Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952705 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age
A Phase 3 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,800
- Enrollment target
NCT00952705: Completed Phase 3 study, sponsored by MedImmune.
NCT00952705 is a Phase 3 study that has completed, run by MedImmune. The registered enrollment target is 1,800 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00952705, a Phase 3 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,800 participants
- Enrollment target
Study Summary
The purpose of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV-BFS; MEDI8662) was at least as immunogenic as two different forms of the commercial vaccine, FluMist, by comparing the strain-specific antibody levels in the blood.
Primary Outcome
Noninferior immune response was assessed by evaluating the upper bound of the 2-sided 95% confidence intervals (CIs) for the ratios of strain-specific HAI GMTs for the specified comparisons. The GMT ratio = GMT in comparator (All FluMist group) divided by the GMT in the Q/LAIV-BFS arm.
Interventions
- BIOLOGICAL FluMist/B/Yamagata
- BIOLOGICAL FluMist/B/Victoria
- BIOLOGICAL Q/LAIV-BFS (MEDI8662)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
What the finished NCT00952705 record still lists
NCT00952705 is an interventional study that assigns participants to a tested intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 3 interventions - of which FluMist/B/Yamagata is the first listed.
NCT00952705 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00952705 about?
NCT00952705 is a clinical study titled "A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age". The purpose of this study was to show that quadrivalent live attenuated influenza vaccine (Q/LAIV-BFS; MEDI8662) was at least as immunogenic as two different forms of the commercial vaccine, FluMist, by comparing the strain-specific antibody levels in the blood.
What is the current status of trial NCT00952705?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2009-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00952705?
The interventions under investigation include: FluMist/B/Yamagata (BIOLOGICAL), FluMist/B/Victoria (BIOLOGICAL), Q/LAIV-BFS (MEDI8662) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00952705?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00952705's enrollment target sits among peer trials
1,800 118th of 2000 higher than 1,876 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia